Cartesian Therapeutics, Inc. (RNAC) Stock Grade

About Cartesian Therapeutics, Inc.'s fundamentals

Cartesian Therapeutics is a biotechnology company with a market capitalization of $211.8 million that is currently unprofitable, with a net loss reported in its latest annual statement and a net margin of -4658.6%. The company experienced a sharp 92.8% year-over-year decline in revenue, reflecting a significant contraction in business activity. As a pre-revenue or early-stage biotech company, it does not pay dividends and lacks a meaningful P/E ratio. The company's financial metrics reflect the typical characteristics of a development-stage biotechnology firm operating at a loss while advancing its pipeline.